Objective: To evaluate the response and the side effects of lressa on the first line treatment in senium advanced stage non-small cell.Methods:Sixteen non-small cell lung cancer patients were observed from November 2005 to September 2007,the date of patients belong to the Second Affiliated Hospital of Dalian Medical University. I was prescribed on the first line at oral dose of 250 mg daily as a continuous dose.Then the response and side-effects of Iressa were evaluated.Results:Among 16 patients,CR,PR,SD,PD were 0% (0/16),37.5% (6/16),50% (8/16),12.5% (2/16) respectively.CR + PR + SD was 87.5% (14/16).Adverse events:rash 37.5% (6/16),dry skin 18.75% (3/16),itching of skin 12.5% (2/16),diarrhea 31.25 (5/16),and hepatic dysfunction (GPT increase) 12.5% (2/16).Conclusion:Iressa is active on the first line treatment in old age advanced stage non-small cell lung cancer.It is well tolerated with adverse events.The quality of life may be improved significantly.